Product Details
Synonym
CEACAM-5, CD66e, CEA, Meconium antigen 100
Source
Cynomolgus CEACAM-5, His Tag (CE5-C52H5) is expressed from human 293 cells (HEK293). It contains AA Gln 35 - Gly 685 (Accession # XP_005589491.1).
Predicted N-terminus: Gln 35
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 73.6 kDa. The protein migrates as 100-170 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a dimer.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Cynomolgus CEACAM-5, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS

The purity of Cynomolgus CEACAM-5, His Tag (Cat. No. CE5-C52H5) is more than 95% and the molecular weight of this protein is around 230-260 kDa verified by SEC-MALS.
Report
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Carcinoembryonic antigen related cell adhesion molecule 5
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
18 Details
- Highest Development Stage:
Phase 3 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















